Gut Microbiome–SCFA Axis as a Pharmacodynamic Modifier of GLP-1 Receptor Agonist Therapy in the South Asian Metabolic Phenotype

GUTMAP-SA is a 24-week prospective observational cohort (N=100 GLP-1RA initiators plus 30 controls)…

• Important Population Gap
• Rigorous Methods
• Narrow Biomarker
• Agent Heterogeneity